Exploring the effect of different surgical methods on the prognosis of patients with colorectal cancer based on multiple omics
Ontology highlight
ABSTRACT:
DISEASE(S): Colorectal Cancer
PROVIDER: 85716 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
Similar Datasets
Project description:Interventions: Response Group:none;None Response Group:Nil
Primary outcome(s): CR;PR;SD;PD;PFS;OS;Gut microbiome;Fecal metabolomics;Immune factor
Study Design: Factorial
| 2689133 | ecrin-mdr-crc
Project description:The aim of this study is to identify early pathogenic changes in ileal gene expression that precede the development of macroscopic disease in inflammatory bowel diseases (IBDs). We focused on two IBD phenotypes that were unlikely to overlap: 1) ileal Crohn’s disease (CD) patients undergoing initial ileocolic resection of diseased ileum; and 2) ulcerative colitis (UC) patients undergoing total colectomy. The Control patients were those patients without IBD undergoing initial right hemicolectomy or total colectomy.
2010-09-26 | GSE24287 | GEO
Project description:The aim of this study is to identify early pathogenic changes in ileal gene expression that precede the development of macroscopic disease in inflammatory bowel diseases (IBDs). We focused on two IBD phenotypes that were unlikely to overlap: 1) ileal Crohn’s disease (CD) patients undergoing initial ileocolic resection of diseased ileum; and 2) ulcerative colitis (UC) patients undergoing total colectomy. The Control patients were those patients without IBD undergoing initial right hemicolectomy or total colectomy. In order to identify early pathogenic changes in the human ileum in inflammatory bowel diseases, we analyzed 99 two-color whole human genome expression profiles (Agilent 4410A) of a test human ileal cRNA probe vs. a common reference human ileal RNA from a Control patient (N17). A minimum of four biopsies were taken from the macroscopically disease-unaffected proximal ileal margin of freshly resected specimens from 47 ileal Crohn's disease patients undergoing initial ileocolic resection, 27 ulcerative colitis patients undergoing total colectomy and 25 Control patients undergoing either right hemicolectomy or total colectomy. The test and common reference probes were synthesized using the Agilent Low Input Linear Amplification Kit. Hybridization was carried out in DNA hybridization chambers, washed and scanned on an Axon GenePix 4000B scanner. The preprocessing, filtering and normalization of the array data was carried out using the R package LIMMA.
2010-09-26 | E-GEOD-24287 | biostudies-arrayexpress
Project description:Colorectal cancer (CRC) is the third most common lethal malignancy in Korea and worldwide. Rectal cancer patients occupy about 30% of CRC patients, and the majority of rectal cancer patients had locally advanced disease at diagnosis. The standard treatment of locally advanced rectal cancer (LARC) is neoadjuvant radiation therapy with concurrent chemotherapy (CCRT) followed by total mesorectal excision (TME). This multidisciplinary team approach improved local tumor control and overall survival of rectal cancer patients. High throughput proteomic analysis and machine learning algorithm identify DUOX2 (dual oxidase 2) as a novel biomarker for prediction of non-complete response after concurrent chemoradiation therapy for rectal cancer.High throughput proteomic analysis and machine learning algorithm identify DUOX2 (dual oxidase 2) as a novel biomarker for prediction of non-complete response after concurrent chemoradiation therapy for rectal cancer.
2023-03-11 | PXD023302 | Pride
Project description:Interventions: Control Group:none;Advanced Adenoma Group:none;Early Colorectal Cancer Group:none
Primary outcome(s): urine metabolomics
Study Design: Factorial
| 2702218 | ecrin-mdr-crc
Project description:Neoadjuvant chemoradiotherapy (CRT) is used in locally advanced rectal cancer when tumours threaten the circumferential resection margin. A variable response to treatment remains, notwithstanding potentially significant morbidity, and no clinically routinely used predictive biomarkers guide decision making. This experimental study aimed to identify significantly differentially expressed proteins between patients responding or not to CRT, using novel temporal proteomic profiling, and to validate any proteins of interest.
2018-03-12 | PXD008436 | Pride
Project description:This study contains multiple -omic data sets. As a follow up to a study on 40 Ulcerative Colitis patients (MSV000082094), 210 fecal samples were analyzed through proteomics using Tandem Mass Tag (TMT) MS3 quantitation. Samples include both Ulcerative Colitis and Crohn's disease patients with healthy volunteers for context. Fecal samples were also analyzed by metabolomics through LCMS2 on a Bruker Maxis qTOF.
2020-11-23 | MSV000086509 | MassIVE
Project description:The molecular mechanisms of clinical response or resistance to therapy were evaluated in colorectal cancer patients in a prospective biomarker discovery project. Rectal adenocarcinomas, biopsied before (diagnostic biopsy) and after (surgical resection) pre-operative short-course radiotherapy [RT] or 5-flurouracil (5-FU)-based chemoradiotherapy [CRT], were profiled using Affymetrix HGU133 Plus 2.0 microarrays. Tumour tissues from untreated controls at diagnosis and surgical resection were used to identify treatment-independent gene expression changes. Candidate resistance biomarkers were identified in this pilot study for validation in a larger cohort.
2009-11-10 | E-MEXP-1901 | biostudies-arrayexpress
Project description:Interventions: Elective or emergent colonic resection, defined using the procedural ICD-10 codes:
32000-00 Limited excision of large intestine with formation of stoma
32000-01 Right hemicolectomy with formation of stoma
32000-02 Laparoscopic limited excision of large intestine with formation of stoma
32000-03 Laparoscopic right hemicolectomy with formation of stoma
32003-00 Limited excision of large intestine with anastomosis
32003-01 Right hemicolectomy with anastomosis
32003-02 Laparoscopic limited excision of large intestine with anastomosis
32003-03 Laparoscopic right hemicolectomy with anastomosis
32004-00 Subtotal colectomy with formation of stoma
32004-01 Extended right hemicolectomy with formation of stoma
32004-02 Laparoscopic subtotal colectomy with formation of stoma
32004-03 Laparoscopic extended right hemicolectomy with formation of stoma
32005-00 Subtotal colectomy with anastomosis
32005-01 Extended right hemicolectomy with anastomosis
32005-02 Laparoscopic subtotal colectomy with anastomosis
32005-03 Laparoscopic extended right hemicolectomy with anastomosis
32006-00 Left hemicolectomy with anastomosis
32006-01 Left hemicolectomy with formation of stoma
32006-02 Laparoscopic left hemicolectomy with anastomosis
32006-03 Laparoscopic left hemicolectomy with formation of stoma
32009-00 Total colectomy with ileostomy
32009-01 Laparoscopic total colectomy with ileostomy
32012-00 Total colectomy with ileorectal anastomosis
32012-01 Laparoscopic total colectomy with ileorectal anastomosis
The procedures were performed at the Austin Hospital, a tertiary hospital with colorectal expertise, over the period of January 2013 and June 2018. Patients were followed-up for 30 days following discharge from the index admission. If no subsequent readmissions occurred within this period, follow-up ceased. If a patient was readmitted within the 30-day period, then the readmission was included, and followi
Primary outcome(s): Costs of complications (as a composite outcome) following Colon resections.
Costs of complications defined as cost of patients with complications less the cost of patients without complications (ie by comparison of patients with and without complications). All costs related to the index admission for colon resection and any consequent readmissions are included. Costs related to preoperative course are not considered. Allocation of costs will be calculated using an activity-based costing methodology. Only in-hospital costs are considered, with both direct and indirect costs assessed to produce a total cost for each patient. Costs for each patient will be obtained from the Austin Health Department of Finance, which maintain an itemised prospective database of all hospital expenses related to each patient.[Costs will be calculated from day of surgery to hospital discharge. Readmissions are considered within 30 days of discharge from the index admission.]
Study Design: Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Retrospective
| 2469243 | ecrin-mdr-crc
